Why the study?
Does edoxaban improve efficacy and safety outcomes compared to standard anticoagulants in patients requiring anticoagulation?
Does edoxaban improve efficacy and safety outcomes compared to standard anticoagulants in patients requiring anticoagulation?
Edoxaban is an effective and safe direct factor Xa inhibitor for VTE prevention/treatment and stroke prevention in AF, offering advantages over traditional vitamin K antagonists.
Answers are grounded in this paper and cite their sources.
Edoxaban may warrant consideration in VTE and AF; leaves open need for comparative effectiveness trials.
Vitamin K antagonists (VKAs) remain the standard therapy for anticoagulation in prevention and treatment of venous thromboembolism (VTE) and for the prevention of stroke in atrial fibrillation (AF). Due to numerous limitations of VKAs, target-specific oral anticoagulants have been developed. Edoxaban is a direct activated factor X inhibitor with attractive features among which are once daily dosing, no need for routine monitoring, and minimal drug-drug interactions. In patients undergoing orthopedic surgery, edoxaban was superior to enoxaparin in preventing VTE. Furthermore, a recent large-scale phase III trial in patients with symptomatic VTE demonstrated that edoxaban was noninferior to warfarin in preventing recurrent VTE and reduced bleeding. In the largest trial of anticoagulation in patients with AF to date, edoxaban was noninferior to warfarin in the prevention of stroke or systemic embolism and reduced bleeding and cardiovascular mortality. This review provides an overview of the pharmacology, clinical trial results, and potential indications for edoxaban.
No takes yet. Share an insight, caveat, or question.
Plitt et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: